CCN2 enhances resistance to cisplatin in a mouse xenograft model.

<p>(A & B) Tumor growth curves of human osteosarcoma cells, which were treated with cisplatin for 45 days. (C) Representative photographs of MG-63/vector, MG-63/CCN2, U-2 OS/control shRNA, and U-2 OS/CCN2 shRNA cells from nude mice. (D) Western blotting was used to determine the protein levels of CCN2, Bcl-xL, survivin, and α-tubulin in tumor cells. Results are expressed as the mean ± SEM.